Home » Stocks » Becton, Dickinson

Becton, Dickinson and Company (BDX)

Stock Price: $258.17 USD -4.16 (-1.59%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 74.84B
Revenue (ttm) 16.92B
Net Income (ttm) 910.00M
Shares Out 289.87M
EPS (ttm) 2.84
PE Ratio 90.90
Forward PE 19.27
Dividend $3.16
Dividend Yield 1.22%

Stock Quote

Trading Day Aug 14, 2020
Last Price $258.17
Previous Close $262.33
Change ($) -4.16
Change (%) -1.59%
Day's Open 261.54
Day's Range 256.66 - 262.30
Day's Volume 1,126,289
52-Week Range 197.75 - 286.72

More Stats

Market Cap 74.84B
Enterprise Value 90.57B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date Jun 8, 2020
Shares Outstanding 289.87M
Float 289.12M
EPS (basic) 2.85
EPS (diluted) 2.84
FCF / Share 9.10
Dividend $3.16
Dividend Yield 1.22%
Earnings Yield 1.10%
FCF Yield 3.31%
Payout Ratio n/a
Shares Short 2.25M
Short Ratio 1.61
Short % of Float 0.89%
Beta 0.98
PE Ratio 90.90
Forward PE 19.27
P/FCF Ratio 30.25
PS Ratio 4.42
PB Ratio 3.10
Revenue 16.92B
Operating Income 1.34B
Net Income 910.00M
Free Cash Flow 2.47B
Net Cash -15.73B
Net Cash / Share -54.28
Gross Margin 48.99%
Operating Margin 7.92%
Profit Margin 4.70%
FCF Margin 14.62%
ROA 2.84%
ROE 3.99%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (19)

Buy 11
Overweight 1
Hold 7
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$286.07*
(10.81% upside)
Low
265
Current: $258.17
High
300
Target: 286.07
*Average 12-month price target from 15 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue17,29015,98312,09312,48310,2828,4468,0547,7087,5847,124
Revenue Growth8.18%32.17%-3.12%21.41%21.74%4.87%4.49%1.64%6.45%-
Gross Profit8,2887,2695,9655,9914,6954,3014,1713,9533,9593,696
Operating Income1,7601,5091,5221,4301,0741,6061,2551,5581,6651,582
Net Income1,2343111,1009766951,1851,2931,1701,2711,318
Shares Outstanding270268228213210192194200217232
Earnings Per Share3.940.604.604.493.355.996.495.595.625.49
EPS Growth556.67%-86.96%2.45%34.03%-44.07%-7.7%16.1%-0.53%2.37%-
Dividend Per Share3.083.002.922.642.402.181.981.801.641.48
Dividend Growth2.67%2.74%10.61%10%10.09%10.1%10%9.76%10.81%-
Operating Cash Flow3,3302,8652,5502,5591,7301,7461,7171,7601,7161,744
Capital Expenditures-957-895-727-693-596-653-588-553-599-626
Free Cash Flow2,3731,9701,8231,8661,1341,0931,1291,2071,1171,118
Cash & Equivalents6201,25314,2001,9071,5192,7502,6082,1811,5631,744
Total Debt19,39021,49518,87011,55112,8223,9713,9704,1662,7201,698
Net Cash / Debt-18,770-20,242-4,670-9,644-11,303-1,221-1,362-1,985-1,15646.08
Assets51,76553,90437,73425,58626,47812,44712,14911,36110,4309,651
Liabilities30,68432,91024,78617,95319,3147,3947,1067,2255,6024,216
Book Value21,08120,99412,9487,6337,1645,0535,0434,1364,8285,435
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Becton, Dickinson and Company
Country United States
Employees 65,000
CEO Thomas E. Polen

Stock Information

Ticker Symbol BDX
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NYSE: BDX
IPO Date April 23, 1962

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. It has a strategic partnership with the Biomedical Advanced Research and Development Authority to develop new manufacturing lines for injection devices. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.